ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
2,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
2,2,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
3,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
4,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
4,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
5,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
6,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
7,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
9,1,Multiple congenital abnormalities,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
10,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
10,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
11,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,1,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
13,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
14,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
14,2,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
14,3,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
14,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
15,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
16,1,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
17,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
18,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
19,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
20,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
21,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
22,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
22,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
23,1,Dermatitis contact,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
24,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
25,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
26,1,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
26,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
27,1,Irritability,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
28,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
